Amgen Loses Bid To Wrap Up Teva Patent Fight
By Megan Stride ( November 22, 2010, 5:28 PM EST) -- Pharmaceutical giant Amgen Inc. has lost its bid for partial summary judgment in a patent spat launched by Teva Pharmaceuticals USA Inc. as part of its effort to market a generic version of Amgen's blood drug Neupogen....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.